Table 2.
Demographics and inclusion criteria
| Sex (total number of patients in all studies) | |
| Male | 9229 (51.7%) |
| Female | 8632 (48.3%) |
| Race (total number of patients in all studies) | |
| White | 4267 (61.7%) |
| Asian | 1776 (25.7%) |
| Black | 447 (6.5%) |
| Other | 424 (6.1%) |
| Race Not Reported (n = 437 studies) | 213/437 studies (48.7%) |
| Median Lines of Prior Therapy, Expansion Cohorts[n (IQR)] | 2 (1–3) |
| Performance Status (n = 429 studies) | |
| ECOG 1 | 71.8% |
| ECOG 2 | 28.2% |
| Inclusion Criteria (n = 437 studies) | |
| Creatinine Clearance | |
| Median Creatinine Clearance (mL/min) | ≥ 50 |
| Creatinine Clearance Not Specified | 182/437 studies (41.6%) |
| Creatinine Clearance Not Included | 33/437 studies (7.6%) |
| Hemoglobin | |
| Median Hemoglobin (g/dL) | ≥ 9 |
| Hemoglobin Not Specified | 186/437 studies (42.6%) |
| Hemoglobin Not Included | 70/437 studies (16.0%) |
| White Blood Cell Count | |
| Median White Blood Cell Count (units/µL) | ≥ 2000 |
| White Blood Cell Count Not Specified | 188/437 studies (43.0%) |
| White Blood Cell Count Not Included | 201/437 studies (46.0%) |
| Neutrophil Count | |
| Median Neutrophil Count (units/µL) | ≥ 1500 |
| Neutrophil Count Not Specified | 184/437 studies (42.1%) |
| Neutrophil Count Not Included | 35/437 studies (8.0%) |
| Platelet Count | |
| Median Platelet Count (units/µL) | ≥ 100,000 |
| Platelet Count Not Specified | 183/437 studies (41.9%) |
| Platelet Count Not Included | 34/437 studies (7.8%) |
| Albumin | |
| Median Albumin (g/dL) | ≥ 3 |
| Albumin Not Specified | 10/437 studies (2.3%) |
| Albumin Not Included | 407/437 studies (93.1%) |
| Transaminases | |
| Median Transaminases (units/L) | ALT/AST ≤ 3 |
| Transaminases Not Specified | 189/437 studies (43.2%) |
| Transaminases Not Included | 33/427 studies (7.6%) |
| Total Bilirubin | |
| Median Total Bilirubin (mg/dL) | Bilirubin ≤ 2 times ULN |
| Total Bilirubin Not Specified | 189/437 studies (43.2%) |
| Total Bilirubin Not Included | 33/437 studies (7.6%) |